Janus kinase inhibitors in immunoinflammatory diseases: 10 years of clinical practice in rheumatology
Despite great advances in the diagnosis and treatment of Immune-mediated inflammatory diseases (IMIDs), which have led to a significant improvement in the prognosis in many patients, the central medical problems of this pathology – restoring the quality of life and reducing mortality to the populati...
Saved in:
Main Authors: | E. L. Nasonov, T. V. Korotaeva |
---|---|
Format: | Article |
Language: | Russian |
Published: |
IMA PRESS LLC
2022-05-01
|
Series: | Научно-практическая ревматология |
Subjects: | |
Online Access: | https://rsp.mediar-press.net/rsp/article/view/3145 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Janus kinase inhibitors in the treatment of psoriatic arthritis
by: E. Yu. Loginova, et al.
Published: (2022-02-01) -
The progress of rheumatology in the 21st century potential uses of upadacitinib in rheumatoid arthritis and other inflammatory rheumatic diseases
by: E. L. Nasonov, et al.
Published: (2020-11-01) -
Clinical significance of Janus kinase inhibitors in the therapy of rheumatoid arthritis: achievements and prospects
by: V. I. Mazurov, et al.
Published: (2019-10-01) -
NEW APPROACHES TO PHARMACOTHERAPY OF RHEUMATOID ARTHRITIS: TOFACITINIB
by: E. L. Nasonov
Published: (2014-06-01) -
Efficacy and safety of tofacitinib for immune-mediated inflammatory rheumatic diseases (Part I)
by: E. L. Nasonov, et al.
Published: (2020-02-01)